KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Kirsten rat sarcoma viral oncogene homolog (KRAS) is a proto-oncogene of the RAS-MAPK pathway. KRAS mutations are present in a variety of malignancies including lung, colorectal, and pancreatic cancer. Until the recent approval of sotorasib, a KRAS G12C inhibitor, lack of targeted therapy for KRAS has resulted in poor prognosis of patients with tumors harboring KRAS mutations. While the conditional approval of sotorasib was a major breakthrough for those patients harboring KRAS G12C mutations, G12C only accounts for a fraction of those with KRAS mutations and eventual resistance to G12C inhibitors are unavoidable. This comprehensive review on KRAS inhibitors covers accumulating evidence on not only the G12C inhibitors but also other therapeutic attempts to tackle KRAS including combination therapy as well as direct inhibition with vaccines, adoptive T cell therapy, proteolysis-targeted chimeras (PROTACs) and CRISPR/Cas9.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
COSMIC: the Catalogue Of Somatic Mutations In Cancer
Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N., Boutselakis, H., Cole, C. G., Creatore, C., Dawson, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1015 · Cited by 4,867
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Self-citationAcquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Self-citationTargeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
DNA vaccines: ready for prime time?
Kutzler, M. A., & Weiner, D. B. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2432 · Cited by 1,077
Research works printed but not linked: 30
- El Osta, 2019, Characteristics and outcomes of patients with metastatic KRAS-mutant lung adenocarcinomas: The Lung Cancer Mutation Consortium Experience, J Thorac Oncol, 14, 876, 10.1016/j.jtho.2019.01.020 · DOI · Paper page
- Biernacka, 2016, The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma, Cancer Genet, 209, 195, 10.1016/j.cancergen.2016.03.001 · DOI · Paper page
- Ostrem, 2016, Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design, Nat Rev Drug Discov, 15, 771, 10.1038/nrd.2016.139 · DOI · Paper page
- Nagasaka, 2020, KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?, Cancer Treat Rev, 84, 101974, 10.1016/j.ctrv.2020.101974 · DOI · Paper page
- Heymach, 2004, Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer, Ann Oncol, 15, 1187, 10.1093/annonc/mdh315 · DOI
- Yam, 2018, A phase II study of tipifarnib and gemcitabine in metastatic breast cancer, Invest New Drugs, 36, 299, 10.1007/s10637-018-0564-2 · DOI
- Sharma, 2002, A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan, Ann Oncol, 13, 1067, 10.1093/annonc/mdf173 · DOI
- Meier, 2012, Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV, Gynecol Oncol, 126, 236, 10.1016/j.ygyno.2012.04.050 · doi:10.1016/j.ygyno.2012.04.050
- Kim, 2005, Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma, Cancer, 104, 561, 10.1002/cncr.21188 · DOI
- Do, 2015, Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer, Invest New Drugs, 33, 720, 10.1007/s10637-015-0212-z · DOI · Paper page
- NDA/BLA Multi-disciplinary Review and Evaluation {NDA 214665} LUMAKRASTM (sotorasib). 214665Orig1s000MultidisciplineR.pdf (fda.gov) Last accessed July 19, 2021.
- Preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor. Presented as a poster at AACR 2021 (abstract number 1259). · DOI · Paper page
- Koltum E, Cregg J, Rice MA, et al. First-in-class, orally bioavailable KRAS G12V (ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRAS G12V mutant cancers. Presented at the American Association for Cancer Research (AACR) Annual Meeting, held virtually April 10-15, 2021. Abstract # 1260. · DOI · Paper page
- Gjertsen MK, Bakka A, Breivik J, et al. Ex vivo ras peptide vaccination in patients with advance pancreatic cancer: results of a phase I/II study. Int J Cancer 1996; 65(4):450-453. doi: 10.1002/(SICI)1097-0215(19960208)65:4<450::AID-IJC10>3.0.CO;2-E. · doi:10.1002/(sici)1097-0215(19960208)65:4<450::aid-ijc10>3.0.co;2-e
- Schwartzentruber, 2011, gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma, N Engl J Med, 364, 2119, 10.1056/NEJMoa1012863 · DOI · Paper page
- Lindinger, 2003, Induction of murine ras oncogene peptide-specific T cell responses by immunization with plasmid DNA-based minigene vectors, Vaccine, 21, 4285, 10.1016/S0264-410X(03)00486-9 · DOI
- Weng, 2014, DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model, Gene Ther, 21, 888, 10.1038/gt.2014.67 · DOI
- Goff, 2016, Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma, J Clin Oncol, 34, 2389, 10.1200/JCO.2016.66.7220 · DOI · Paper page
- Rosenberg, 2015, Adoptive cell transfer as personalized immunotherapy for human cancer, Science, 348, 62, 10.1126/science.aaa4967 · DOI · Paper page
- Rosenberg, 2011, Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy, Clin Cancer Res, 17, 4550, 10.1158/1078-0432.CCR-11-0116 · DOI · Paper page
- Lu, 2017, Treatment of patients with metastatic cancer using a major histocompatibility complex class II-restricted T-cell receptor targeting the cancer germline antigen MAGE-A3, J Clin Oncol, 35, 3322, 10.1200/JCO.2017.74.5463 · DOI · Paper page
- Robbins, 2015, A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response, Clin Cancer Res, 21, 1019, 10.1158/1078-0432.CCR-14-2708 · DOI · Paper page
- Zacharakis, 2018, Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer, Nat Med, 24, 724, 10.1038/s41591-018-0040-8 · DOI · Paper page
- Tran, 2015, Immunogenicity of somatic mutations in human gastrointestinal cancers, Science, 350, 1387, 10.1126/science.aad1253 · DOI · Paper page
- Yossef R, Tran E, Deniger DC, Gros A, Pasetto A, Parkhurst MR, et al. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. JCI Insight 2018;3:pii: 122467. doi: 10.1172/jci.insight.122467. · DOI · Paper page
- Cafri, 2019, Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients, Nat Commun, 10, 449, 10.1038/s41467-019-08304-z · DOI · Paper page
- Morgan, 2013, Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy, J Immunother, 36, 133, 10.1097/CJI.0b013e3182829903 · DOI · Paper page
- Scudellari, 2019, Protein-slaying drugs could be the next blockbuster therapies, Nature, 567, 298, 10.1038/d41586-019-00879-3 · DOI
- Cheng, 2020, Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer, J Med Chem, 63, 7892, 10.1021/acs.jmedchem.0c00929 · DOI · Paper page
- Bannoura SF, Uddin MH, Nagasaka, et al. Targeting KRAS in pancreatic cancer: new drugs on the horizon. Cancer Metastasis Rev 2021 Sep 9. doi: 10.1007/s10555-021-09990-2. Online ahead of print. · DOI
Cited by
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
KRAS in NSCLC: State of the Art and Future Perspectives
Cascetta, P., Marinello, A., Lazzari, C., Gregorc, V., Planchard, D., Bianco, R., Normanno, N., & Morabito, A. (2022) · Cancers · doi:10.3390/cancers14215430 · Cited by 76
“, JAB23000) are currently being investigated with promising preclinical results [79,80].”
BackgroundSantarpia, M., Ciappina, G., Spagnolo, C. C., Squeri, A., Passalacqua, M. I., Aguilar, A., Gonzalez-Cao, M., Giovannetti, E., Silvestris, N., & Rosell, R. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-639 · Cited by 65
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Ash, L. J., Busia-Bourdain, O., Okpattah, D., Kamel, A., Liberchuk, A., & Wolfe, A. L. (2024) · Current Oncology · doi:10.3390/curroncol31040150 · Cited by 68
Yu, I., Dakwar, A., & Takabe, K. (2023) · Cells · doi:10.3390/cells12020258 · Cited by 40
“After administration, APCs then translate the mRNA to a neoantigen peptide and present it on MHC molecules, stimulating the cytotoxic T-lymphocyte and memory T cell immune response against tumor cells that express the same neoantigen [92].”
Background
Metadata
- Authors
- Nagasaka, M., Potugari, B., Nguyen, A., Sukari, A., Azmi, A. S., & Ou, S.-H. I.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2021-12
- Volume
- 101
- Pages
- 102309
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W3210374936
- Cited by
- 76
- References
- 32
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- National Cancer Institute (R01CA24060701, R37 5R37CA215427)
- Sky Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond. https://app.cochat.ai/papers/10.1016/j.ctrv.2021.102309
- The paper
- Nagasaka, M., Potugari, B., Nguyen, A., Sukari, A., Azmi, A. S., & Ou, S.-H. I. (2021). KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2021.102309
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.